New inhibitors of human cytomegalovirus (HCMV) on the horizon

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 5, 2003, Pages 1079-1083

  De Clerq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antivirals; Human cytomegalovirus

Indexed keywords

1 (BETA DEXTRO RIBOFURANOSYL) 2 BROMO 5,6 DICHLOROBENZIMIDAZOLE; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 CHLORO 3 PYRIDIN 3 YL 5,6,7,8 TETRAHYDROINDOLIZINE 1 CARBOXAMIDE; 4 HYDROXYQUINOLINE 3 CARBOXAMIDE; 7,8 DIHYDROISOQUINOLINE 6 CARBOXY[2 (1 INDOL 3 YL)ETHYL]AMIDE; ACETAMIDE DERIVATIVE; AMINOTHIAZOLYLPHENYL DERIVATIVE; ANHYDROHEXITOL GUANINE; ANTIVIRUS AGENT; BAY 571293; BENZENE DERIVATIVE; BENZIMIDAVIR; BILS 179; CIDOFOVIR; CMV 423; CYCLOHEXENYL GUANINE; FOMIVIRSEN; FOSCARNET SODIUM; GANCICLOVIR; GUANINE DERIVATIVE; GUANOSINE DERIVATIVE; HEXADECYCLOXYPROPYL CIDOFOVIR; N [5 (AMINOSULPHONYL) 4 METHYL 1,3 THIAZOL 2 YL] N METHYL 2 [4 (2 PYRIDINYL)PHENYL]ACETAMIDE; NEW DRUG; PNU 181465; PROBENECID; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; SYNGUANOL; TOMEGLOVIR; UNCLASSIFIED DRUG; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BONE MARROW SUPPRESSION; DRUG APPROVAL; DRUG INDICATION; DRUG STRUCTURE; DRUG TARGETING; GENE MUTATION; GRANULOCYTOPENIA; HUMAN; HUMAN CYTOMEGALOVIRUS; NEPHROTOXICITY; RETINITIS; THROMBOCYTOPENIA; VIRUS INHIBITION; VIRUS ISOLATION;

ANIMALS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG DESIGN; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037764114     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg205     Document Type: Article

References (20)

1. De Clercq, E. (2001). Antiviral drugs: current state of the art. Journal of Clinical Virology 22, 73-89.
2. De Clercq, E. (1998). Antiviral agents that are active against CMV: potential of cidofovir for the treatment of CMV and other virus infections. Monographs in Virology 21, 193-214.
3. Snoeck, R., Andrei, G., Bodaghi, B., Lagneaux, L., Daelemans, D., De Clercq, E. et al. (2002). 2-Chloro-3-pyridin-3-yl-5,6,7,8-tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral Research 55, 413-24.
4. Jacobson, J. G., Renau, T. E., Nassiri, M. R., Sweier, D. G., Breitenbach, J. M., Townsend, L. B. et al. (1999). Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus. Antimicrobial Agents and Chemotherapy 43, 1888-94.
5. Bedard, J., May, S., L'Heureux, L., Stamminger, T., Copsey, A., Drach, J. et al. (2000). Antiviral properties of a series of 1,6-naphthyridine and 7,8-dihydroisoquinoline derivatives exhibiting potent activity against human cytomegalovirus. Antimicrobial Agents and Chemotherapy 44, 929-37.
6. Oien, N. L., Brideau, R. J., Hopkins, T. A., Wieber, J. L., Knechtel, M. L., Shelly, J. A. et al. (2002). Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitors. Antimicrobial Agents and Chemotherapy 46, 724-30.
7. Bueger, I., Reefschlaeger, J., Bender, W., Eckenberg, P., Popp, A., Weber, O. et al. (2001). A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. Journal of Virology 75, 9077-86.
8. Krosky, P. M., Underwood, M. R., Turk, S. R., Feng, K. W., Jain, R. K., Ptak, R. G. et al. (1998). Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. Journal of Virology 72, 4721-8.
9. Biron, K. K., Harvey, R. J., Chamberlain, S. C., Good, S. S., Smith III, A. A., Davis, M. G. et al. (2002). Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrobial Agents and Chemotherapy 46, 2365-72.
10. Zimmermann, A., Wilts, H., Lenhardt, M., Hahn, M. & Mertens, T. (2000). Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Research 48, 49-60.
11. Krosky, P. M., Baek, M.-C. & Coen, D. M. (2002). The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. Journal of Virology 77, 905-14.
12. Koszalka, G. W., Johnson, N. W., Good, S. S., Boyd, L., Chamberlain, S. C., Townsend, L. B. et al. (2002). Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrobial Agents and Chemotherapy 46, 2373-80.
13. Lalezari, J. P., Aberg, J. A., Wang, L. H., Wire, M. B., Miner, R., Sowden, W. et al. (2002). Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrobial Agents and Chemotherapy 46, 2969-76.
14. Crute, J. J., Grygon, C. A., Hargrave, K. D., Simoneau, B., Faucher, A.-M., Bolger, G. et al. (2002). Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nature Medicine 8, 386-91.
15. Kleymann, G., Fischer, R., Betz, U. A. K., Hendrix, M., Bender, W., Schneider, U. et al. (2002). New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nature Medicine 8, 392-8.
16. Betz, U. A. K., Fischer, R., Kleymann, G., Hendrix, M. & Rübsamen-Waigmann, H. (2002). Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293. Antimicrobial Agents and Chemotherapy 46, 1766-72.
17. De Clercq, E., Andrei, G., Snoeck, R., De Bolle, L., Naesens, L., Degrève, B. et al. (2001). Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents. Proceedings of the XIV International Round Table on Nucleosides, Nucleotides and their Biological Applications, San Francisco, USA, 10-14 September 2000. Nucleosides, Nucleotides and Nucleic Acids 20, 271-85.
18. De Clercq, E., Naesens, L., De Bolle, L., Schols, D., Zhang, Y. & Neyts, J. (2001). Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Reviews in Medical Virology 11, 381-95.
19. Kern, E. R., Hartline, C., Harden, E., Keith, K., Rodriguez, N., Beadle, J. R. et al. (2002). Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir. Antimicrobial Agents and Chemotherapy 46, 991-5.
20. De Clercq, E. (2002). Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends in Pharmacological Sciences 23, 456-8.